Lexicon Pharmaceuticals Reports Fourth Quarter and Full-Year 2017 Financial Results and Provides a Business Update
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/20/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
Needham & Company Downgrades Lexicon Pharmaceuticals (LXRX) to Hold
February 23, 2018 7:14 AM ESTNeedham & Company downgraded Lexicon Pharmaceuticals (NASDAQ: LXRX) from Buy to Hold.
Analsyt Alan Carr commented, "Lexicon reported $5.4M U.S. Xermelo 4Q17 sales (+3% q/q), below our and consensus $7.5M ests. Challenges include low number of patient starts and a large number... More
Lexicon Pharmaceuticals (LXRX) PT Lowered to $25 at Stifel; 'Despite Slow Xermelo Progress, We Still Can’t Reconcile Valuation Here'
February 22, 2018 5:20 PM ESTStifel lowered its price target on Lexicon Pharmaceuticals (NASDAQ: LXRX) to $25.00 (from $27.00) while maintaining a Buy rating.
... More